Literature DB >> 9531502

Involvement of the Ras/extracellular signal-regulated kinase signalling pathway in the regulation of ERCC-1 mRNA levels by insulin.

W Lee-Kwon1, D Park, M Bernier.   

Abstract

Expression of DNA repair enzymes, which includes ERCC-1, might be under the control of hormonal and growth factor stimulation. In the present study it was observed that insulin increased ERCC-1 mRNA levels both in Chinese hamster ovary cells overexpressing human insulin receptors (HIRc cells) and in fully differentiated 3T3-L1 adipocytes. To investigate the mechanisms underlying the increase in ERCC-1 gene expression in HIRc cells, we used a variety of pharmacological tools known to inhibit distinct signalling pathways. None of these inhibitors affected the amount of ERCC-1 mRNA in unstimulated cells. The pretreatment of cells with two chemically unrelated phosphatidylinositol 3'-kinase inhibitors, wortmannin and LY294002, failed to block the doubling of ERCC-1 mRNA content by insulin. Similarly, inhibition of pp70 S6 kinase by rapamycin had no apparent effects on this insulin response. In contrast, altering the p21(ras)-dependent pathway with either manumycin, an inhibitor of Ras farnesylation, or PD98059, an inhibitor of the mitogen-activated protein kinase/extracellular signal-regulated protein kinase (ERK) kinase, suppressed the induction of ERCC-1 mRNA by insulin (P<0.001). Furthermore inhibition of RNA and protein synthesis negatively regulated the expression of this insulin-regulated gene (P<0.005). These results suggest that insulin enhances ERCC-1 mRNA levels by the activation of the Ras-ERK-dependent pathway without the involvement of the phosphatidylinositol 3'-kinase/pp70 S6 kinase.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531502      PMCID: PMC1219393          DOI: 10.1042/bj3310591

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  59 in total

Review 1.  Evidence that mammalian cells possess homologous recombinational repair pathways.

Authors:  L H Thompson
Journal:  Mutat Res       Date:  1996-06-12       Impact factor: 2.433

2.  A peptide-based protein-tyrosine phosphatase inhibitor specifically enhances insulin receptor function in intact cells.

Authors:  H K Kole; M J Garant; S Kole; M Bernier
Journal:  J Biol Chem       Date:  1996-06-14       Impact factor: 5.157

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  High glucose induces DNA damage in cultured human endothelial cells.

Authors:  M Lorenzi; D F Montisano; S Toledo; A Barrieux
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

5.  ERCC1/ERCC4 5'-endonuclease activity as a determinant of hypoxic cell radiosensitivity.

Authors:  D Murray; A Macann; J Hanson; E Rosenberg
Journal:  Int J Radiat Biol       Date:  1996-03       Impact factor: 2.694

6.  Analysis of the signaling pathway involved in the regulation of hexokinase II gene transcription by insulin.

Authors:  H Osawa; C Sutherland; R B Robey; R L Printz; D K Granner
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

7.  Molecular cloning of a human DNA repair gene.

Authors:  A Westerveld; J H Hoeijmakers; M van Duin; J de Wit; H Odijk; A Pastink; R D Wood; D Bootsma
Journal:  Nature       Date:  1984 Aug 2-8       Impact factor: 49.962

8.  Mechanism of action of dichloro-beta-D-ribofuranosylbenzimidazole: effect on in vitro transcription.

Authors:  R Zandomeni; B Mittleman; D Bunick; S Ackerman; R Weinmann
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

9.  Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation.

Authors:  T Nagase; S Kawata; S Tamura; Y Matsuda; Y Inui; E Yamasaki; H Ishiguro; T Ito; Y Matsuzawa
Journal:  Int J Cancer       Date:  1996-03-01       Impact factor: 7.396

10.  Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor.

Authors:  T Ito; S Kawata; S Tamura; T Igura; T Nagase; J I Miyagawa; E Yamazaki; H Ishiguro; Y Matasuzawa
Journal:  Jpn J Cancer Res       Date:  1996-02
View more
  6 in total

1.  Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.

Authors:  Pradip De; Yuling Sun; Jennifer H Carlson; Lori S Friedman; Brian R Leyland-Jones; Nandini Dey
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

2.  Single cell transcriptomics based-MacSpectrum reveals novel macrophage activation signatures in diseases.

Authors:  Chuan Li; Antoine Menoret; Cullen Farragher; Zhengqing Ouyang; Christopher Bonin; Paul Holvoet; Anthony T Vella; Beiyan Zhou
Journal:  JCI Insight       Date:  2019-04-16

3.  Correlation Analysis and Prognostic Impact of (18)F-FDG PET and Excision Repair Cross-Complementation Group 1 (ERCC-1) Expression in Non-Small Cell Lung Cancer.

Authors:  Yong Hyu Jeong; Choong-Kun Lee; Kwanhyeong Jo; Sang Hyun Hwang; Jongtae Cha; Jeong Won Lee; Mijin Yun; Arthur Cho
Journal:  Nucl Med Mol Imaging       Date:  2014-11-08

Review 4.  Are RAS mutations predictive markers of resistance to standard chemotherapy?

Authors:  Yohann Loriot; Pierre Mordant; Eric Deutsch; Ken André Olaussen; Jean-Charles Soria
Journal:  Nat Rev Clin Oncol       Date:  2009-07-14       Impact factor: 66.675

5.  Differential Regulation of LET-7 by LIN28B Isoform-Specific Functions.

Authors:  Rei Mizuno; Priya Chatterji; Sarah Andres; Kathryn Hamilton; Lauren Simon; Shawn W Foley; Arjun Jeganathan; Brian D Gregory; Blair Madison; Anil K Rustgi
Journal:  Mol Cancer Res       Date:  2018-01-12       Impact factor: 5.852

6.  Polymorphism in ERCC1 confers susceptibility of coronary artery disease and severity of coronary artery atherosclerosis in a Chinese Han population.

Authors:  Shuai Zhang; Xue-Bin Wang; Ya-di Han; Chen-Ling Xiong; Ye Zhou; Chen Wang; Ze-Jin Liu; Na Yang; Fang Zheng
Journal:  Sci Rep       Date:  2017-07-25       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.